Cited 9 times in
A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.date.accessioned | 2014-12-20T16:49:45Z | - |
dc.date.available | 2014-12-20T16:49:45Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/93456 | - |
dc.description.abstract | PURPOSE: It is unknown whether cilostazol pretreatment reduces postprocedural myonecrosis (PPMN). Cilostazol pretreatment reduces PPMN after percutaneous coronary intervention (PCI). MATERIALS AND METHODS: A total of 120 patients with stable angina scheduled for elective PCI were randomly assigned to a 7-day pretreatment with Cilostazol (200 mg/day) or to a control group. Creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured at baseline and at 6 and 24 hours after PCI. The primary end-point was the occurrence of PPMN, defined as any CK-MB elevation above the upper normal limit (UNL). Aspirin and clopidogrel were co-administered for 7 days before PCI, and resistance to these agents was then assayed using the VerifyNow System. RESULTS: There was no difference in baseline characteristics between the final analyzable cilostazol (n=54) and the control group (n=56). Despite a significantly greater % inhibition of clopidogrel in the cilostazol group (39±23% versus 25±22%, p=0.003), the incidence of PPMN was similar between the cilostazol group (24%) and the control group (25%, p=1.000). The rate of CK-MB elevation at ≥3 times UNL was also similar between the two groups (6% versus 5%, p=0.583). The incidence of cTnI increase over the UNL or to 3 times the UNL was not different between the two groups. There was no significant difference in terms of the rate of adverse events during follow- up, although the cilostazol group showed a tendency to have a slightly higher incidence of entry site hematoma. CONCLUSION: This trial demonstrated that adjunctive cilostazol pretreatment might not significantly reduce PPMN after elective PCI in patients with stable angina. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 717~726 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angina, Stable/drug therapy | - |
dc.subject.MESH | Angina, Stable/enzymology | - |
dc.subject.MESH | Angina, Stable/therapy | - |
dc.subject.MESH | Angioplasty, Balloon, Coronary/adverse effects* | - |
dc.subject.MESH | Creatine Kinase, MB Form/blood | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Heart Injuries/etiology | - |
dc.subject.MESH | Heart Injuries/prevention & control | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardium/pathology | - |
dc.subject.MESH | Necrosis | - |
dc.subject.MESH | Phosphodiesterase 3 Inhibitors/administration & dosage* | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Tetrazoles/administration & dosage* | - |
dc.title | A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Seung Jin Oh | - |
dc.contributor.googleauthor | Se-Jung Yoon | - |
dc.contributor.googleauthor | Dong Woon Jeon | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Joo Young Yang | - |
dc.identifier.doi | 10.3349/ymj.2011.52.5.717 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 21786434 | - |
dc.subject.keyword | Coronary disease | - |
dc.subject.keyword | myocardial infarction | - |
dc.subject.keyword | stents | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | Kim, Byeong Keuk | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 52 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 717 | - |
dc.citation.endPage | 726 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.52(5) : 717-726, 2011 | - |
dc.identifier.rimsid | 28246 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.